The latest from CDMOs, CMOs, and suppliers featuring Thermo Fisher Scientific, Wacker, Corealis Pharma, ChemWerth, LFB Biomanufacturing and The Celonic Group.  

Chemicals/Chemical API Manufacturing 
* ChemWerth Appoints New CEO 
Biologics Manufacturing 
* Wacker Opens New $107-M mRNA Center 
* LFB Biomanufacturing To Invest $21 M to Expand Biologics Mfg Facility
* Celonic Opens New Biologics Development Center & Pilot Plant 
Formulation Development/Drug Product Manufacturing 
* Corealis Pharma Invests $10 M To Expand Oral Solid Dosage Mfg
General 
* Thermo Fisher Invests $58 M In New Research Laboratory   

---

Chemicals/Chemical API Manufacturing 

ChemWerth Appoints New CEO 
ChemWerth, a Woodbridge, Connecticut-based suppliers of generic active active pharmaceutical ingredients, has announced that Pete Werth III will succeed his father, and company founder Peter J. Werth, who has stepped down after leading the company for 42 years.  

Peter J. Werth founded ChemWerth in 1982. He will continue to serve as Chairman of ChemWerth’s Board of Directors and will remain engaged in product selection and development.  

Pete Werth III, who has been involved in the company since its inception, succeeds his father as the new President of ChemWerth. Werth III has held several leadership positions over the years. He most recently served as a member of ChemWerth’s Board of Directors and was a senior advisor to the company. 

Source: ChemWerth 

---

Biologics Manufacturing 

Wacker Opens New $107-M mRNA Center 
Wacker Biotech, a CDMO of biologics and a subsidiary of Wacker Chemie AG, has opened an mRNA Competence Center at its biotech site in Halle (Saale), Germany, with an investment of over EUR 100 million ($107 million). The new facility enables the large-scale production of active ingredients based on messenger ribonucleic acid (mRNA). Four new production lines have more than tripled the site’s capacity. Some of the new capacity will be made available to the German government as part of its pandemic-preparedness plan in order to supply Germany with vaccines as and when required.  

Source: Wacker 

---

LFB Biomanufacturing To Invest $21 M To Expand Biologics Mfg Facility 
LFB Biomanufacturing, an Alès, France-based CDMO of biologics, has announced an investment of more than 20 million ($21 million) to expand capacity at it site in Alès, France. The investment will doubled production capacities of 2 x 2,000 liters. This expansion will also include development and analytical service laboratories and a warehouse for raw materials.  

Source: LFB Biomanufacturing 

---

Celonic Opens New Biologics Development Center & Pilot Plant 
The Celonic Group, a Basel, Switzerland-based biologics CDMO, has opened a new biologics development center and pilot plant in Basel, Switzerland. 

Source: The Celonic Group 

---

Formulation Development/Drug Product Manufacturing 

Corealis Pharma Invests $10 M To Expand Oral Solid Dosage Mfg 
Corealis Pharma, a Laval, Quebec, Canada-based contract provider of formulation development and clinical supplies manufacturing of oral solid dosage forms has inaugurated its $10-million expansion of its facility in Laval, Quebec, Canada. The expansion expanded the company’s footprint from 33,000 to 63,000 square feet, which included the installation of new laboratories.

Source: Corealis Pharma

---

General 

Thermo Fisher Invests $58 M in New Research Laboratory 
The PPD clinical research business of Thermo Fisher Scientific has added a new $58-million clinical research laboratory building at its GMP lab in Middleton, Wisconsin.  

The new 72,500-square-foot building increases the site’s chemistry, manufacturing and control (CMC) analytical capabilities. The GMP site provides analytical services for small molecules and biologics, including bio/pharmaceuticals, inhaled pharmaceuticals and device testing, cell and gene therapies, protein characterization, mass spectrometry analysis for all phases of drug development. In addition, the expansion includes a Biosafety Level 2 laboratory that includes a liquid chromatography–mass spectrometry and protein characterization space, two large-molecular suites with access-controlled pre- and post-amplification labs, and two large general-use labs. The expansion will add up to 350 scientists and laboratory support professionals to the almost 2,300 employees working across the research campus. 

Source: Thermo Fisher Scientific